Skeletal metastases from breast cancer: Imaging with nuclear medicine

G. J. R. Cook; I. Fogelman

doi:10.1016/s0001-2998(99)80031-2

Skeletal metastases from breast cancer: Imaging with nuclear medicine

G. J. R. Cook, I. Fogelman

Research output: Contribution to journal › Article › peer-review

52 Citations (Scopus)

Abstract

Breast cancer is a disease that commonly metastasizes to bone, increasing morbidity, mortality, and health service costs. The 99m technetium (Tc-99m) diphosphonate bone scan historically has played a significant part in the evaluation of skeletal disease and continues to be one of the most clinically utilized investigations in the staging and follow up of breast cancer patients. More tumor-specific radiopharmaceuticals are now being evaluated and, in particular, 18-fluoro-2-deoxyglucose positron emission tomography ((18)FDG PET) may have a greater role in this disease in the future. Copyright (C) 1999 by W.B. Saunders Company.

Original language	Undefined/Unknown
Pages (from-to)	69-79
Number of pages	11
Journal	Seminars in Nuclear Medicine
Volume	29
Issue number	1
DOIs	https://doi.org/10.1016/s0001-2998(99)80031-2
Publication status	Published - Jan 1999

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s0001-2998(99)80031-2

Cite this

@article{0062a7524e8b4b36ab963cbd5d2d9e16,

title = "Skeletal metastases from breast cancer: Imaging with nuclear medicine",

abstract = "Breast cancer is a disease that commonly metastasizes to bone, increasing morbidity, mortality, and health service costs. The 99m technetium (Tc-99m) diphosphonate bone scan historically has played a significant part in the evaluation of skeletal disease and continues to be one of the most clinically utilized investigations in the staging and follow up of breast cancer patients. More tumor-specific radiopharmaceuticals are now being evaluated and, in particular, 18-fluoro-2-deoxyglucose positron emission tomography ((18)FDG PET) may have a greater role in this disease in the future. Copyright (C) 1999 by W.B. Saunders Company.",

author = "Cook, {G. J. R.} and I. Fogelman",

note = "M1 - 1 Times Cited: 20",

year = "1999",

month = jan,

doi = "10.1016/s0001-2998(99)80031-2",

language = "Undefined/Unknown",

volume = "29",

pages = "69--79",

journal = "Seminars in Nuclear Medicine",

issn = "0001-2998",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Skeletal metastases from breast cancer

T2 - Imaging with nuclear medicine

AU - Cook, G. J. R.

AU - Fogelman, I.

N1 - M1 - 1 Times Cited: 20

PY - 1999/1

Y1 - 1999/1

N2 - Breast cancer is a disease that commonly metastasizes to bone, increasing morbidity, mortality, and health service costs. The 99m technetium (Tc-99m) diphosphonate bone scan historically has played a significant part in the evaluation of skeletal disease and continues to be one of the most clinically utilized investigations in the staging and follow up of breast cancer patients. More tumor-specific radiopharmaceuticals are now being evaluated and, in particular, 18-fluoro-2-deoxyglucose positron emission tomography ((18)FDG PET) may have a greater role in this disease in the future. Copyright (C) 1999 by W.B. Saunders Company.

AB - Breast cancer is a disease that commonly metastasizes to bone, increasing morbidity, mortality, and health service costs. The 99m technetium (Tc-99m) diphosphonate bone scan historically has played a significant part in the evaluation of skeletal disease and continues to be one of the most clinically utilized investigations in the staging and follow up of breast cancer patients. More tumor-specific radiopharmaceuticals are now being evaluated and, in particular, 18-fluoro-2-deoxyglucose positron emission tomography ((18)FDG PET) may have a greater role in this disease in the future. Copyright (C) 1999 by W.B. Saunders Company.

U2 - 10.1016/s0001-2998(99)80031-2

DO - 10.1016/s0001-2998(99)80031-2

M3 - Article

SN - 0001-2998

VL - 29

SP - 69

EP - 79

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

IS - 1

ER -